Evidence map›Paper›PMID 29201918›Full record

ReviewJournal of diabetes research2017

The Role of Insulin Receptor Isoforms in Diabetes and Its Metabolic and Vascular Complications.

O Escribano, N Beneit, C Rubio-Longás, A R López-Pastor, A Gómez-Hernández

Open access · goldAbstract readReview
In one paragraph

Review in Journal of diabetes research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 64 citations in OpenAlex.

  1. Trial
  2. Antibody-Based Biologics for CNS Disorders.Antibodies (Basel, Switzerland) · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. mRNA Transcript Variants Expressed in Mammalian Cells.International journal of molecular sciences · 2025
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Changes in Cells Associated with Insulin Resistance.International journal of molecular sciences · 2024
    Review
  15. Insulin Resistance: The Increased Risk of Cancers.Current oncology (Toronto, Ont.) · 2024
    Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

O EscribanoBiochemistry and Molecular Biology II Department, School of Pharmacy, Complutense University of Madrid, Madrid, Spain.ORCID 0000-0002-8249-1645
N BeneitBiochemistry and Molecular Biology II Department, School of Pharmacy, Complutense University of Madrid, Madrid, Spain.
C Rubio-LongásBiochemistry and Molecular Biology II Department, School of Pharmacy, Complutense University of Madrid, Madrid, Spain.
A R López-PastorBiochemistry and Molecular Biology II Department, School of Pharmacy, Complutense University of Madrid, Madrid, Spain.
A Gómez-HernándezBiochemistry and Molecular Biology II Department, School of Pharmacy, Complutense University of Madrid, Madrid, Spain.ORCID 0000-0002-2742-4298
Universidad Complutense de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The insulin receptor (IR) presents by alternative splicing two isoforms: IRA and IRB. The differential physiological and pathological role of both isoforms is not completely known, and it is determinant the different binding affinity for insulin-like growth factor. IRB is more abundant in adult tissues and it exerts mainly the metabolic actions of insulin, whereas IRA is mainly expressed in fetal and prenatal period and exerts mitogenic actions. However, the change in the expression profile of both IR isoforms and its dysregulation are associated with the development of different pathologies, such as cancer, insulin resistance, diabetes, obesity, and atherosclerosis. In some of them, there is a significant increase of IRA/IRB ratio conferring a proliferative and migratory advantage to different cell types and favouring IGF-II actions with a sustained detriment in the metabolic effects of insulin. This review discussed specifically the role of IR isoforms as well as IGF-IR in diabetes and its associated complications as obesity and atherosclerosis. Future research with new IR modulators might be considered as possible targets to improve the treatment of diabetes and its associated complications.

Indexed as

Alternative SplicingDiabetes Mellitus, Type 2HumansInsulinInsulin ResistanceProtein IsoformsReceptor, InsulinSignal TransductionInsulinProtein IsoformsReceptor, Insulin

Identifiers

PMID29201918
PMCPMC5671728
OpenAlexW2766017652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.